Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.

摘要

Dear Editor, Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma that is characterized by a typical cytological presentation, the presence of the t(11;14)(q13; q32) chromosomal translocation, and overexpression of cyclin D1. MCL has a low response rate and short progression-free survival (PFS) after conventional therapy. In refractory or relapsed MCL, the prognosis is even worse. Several novel therapeutic approaches have been proposed, including monoclonal antibodies, radioirnmunotherapy, proteasome inhibitors, m-TOR inhibitors, and the immunomodulatory drugs thalidomide and lenalidomide. In our patient with refractory MCL, the use of lenalidomide as single agent therapy allowed for complete cytological, phenotypic, and cytogenetic remission in a very short period of time.